Tang Capital Management’s Fate Therapeutics FATE Stock Holding History

Tang Capital Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,167,773	Closed	-$1.4M	–	49
2026 Q1	$1.4M	Hold	1,167,773	–	–	0.07%	48
2025 Q4	$1.15M	Sell	1,167,773 -700,000	-37%	-$841K	0.06%	70
2025 Q3	$2.35M	Hold	1,867,773	–	–	0.09%	121
2025 Q2	$2.09M	Hold	1,867,773	–	–	0.11%	115
2025 Q1	$1.48M	Buy	1,867,773 +11,819	+0.6%	+$14.5K	0.08%	136
2024 Q4	$3.06M	Buy	1,855,954 +1,155,954	+165%	+$2.91M	0.2%	91
2024 Q3	$2.45M	Hold	700,000	–	–	0.18%	92
2024 Q2	$2.3M	Hold	700,000	–	–	0.23%	75
2024 Q1	$5.14M	Hold	700,000	–	–	0.54%	57
2023 Q4	$2.62M	Hold	700,000	–	–	0.24%	83
2023 Q3	$1.48M	Hold	700,000	–	–	0.21%	85
2023 Q2	$3.33M	Hold	700,000	–	–	0.49%	56
2023 Q1	$3.99M	Buy	+700,000	New	+$4.22M	0.59%	46

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Tang Capital Management's FATE Position: Q2 2026 in Review

Tang Capital Management sold out of Fate Therapeutics (FATE) in Q2 2026, closing a stake of 1,167,773 shares — an estimated $1.4M sold.

Tang Capital Management first reported a position in FATE in Q1 2023 and held it in 13 quarters. The position peaked at $5.14M in Q1 2024. 155 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

Tang Capital Management reported no remaining Fate Therapeutics position as of Q2 2026 after selling out during the quarter.
Tang Capital Management sold 1,167,773 Fate Therapeutics shares in Q2 2026, an estimated $1.4M.
Tang Capital Management first reported a position in Fate Therapeutics in Q1 2023 and held it in 13 quarters.
Tang Capital Management's Fate Therapeutics position peaked at $5.14M in Q1 2024.
155 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Tang Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.